Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare immune diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product is also commercially available in Europe (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic immune thrombocytopenia in adult patients.

Company profile
Ticker
RIGL
Exchange
Website
CEO
Raul Rodriguez
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
943248524
RIGL stock data
News

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
3 Aug 22
Rigel Pharma Expands Blood Cancer Portfolio With Forma Therapeutics Licensing Pact
3 Aug 22
Rigel Pharmaceuticals: Q2 Earnings Insights
2 Aug 22
Rigel Pharmaceuticals Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $29.80M Beat $23.65M Estimate
2 Aug 22
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
2 Aug 22
Press releases
Thinking about buying stock in Advanced Micro Devices, Endo International, Faraday Future Intelligent Electric, Robinhood Markets, or Rigel Pharmaceuticals?
3 Aug 22
Rigel Reports Second Quarter 2022 Financial Results and Provides Business Update
2 Aug 22
Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia
2 Aug 22
Rigel Announces Conference Call and Webcast to Report Second Quarter 2022 Financial Results and Business Update
26 Jul 22
Thinking about buying stock in Energy Focus, Ford Motor, Clovis Oncology, Li Auto, or Rigel Pharmaceuticals?
22 Jun 22
Analyst ratings and price targets
Current price
Average target
$3.01
Low target
$0.80
High target
$7.00
BMO Capital
Maintains
$3.00
B. Riley Securities
Maintains
$1.25
Citigroup
Downgraded
$0.80
HC Wainwright & Co.
Maintains
$7.00
Calendar
2 Aug 22
12 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 27.2M | 27.2M | 27.2M | 27.2M | 27.2M | 27.2M |
Cash burn (monthly) | (no burn) | 4.8M | 4.5M | 7.06M | 4.3M | 5.66M |
Cash used (since last report) | n/a | 6.95M | 6.51M | 10.22M | 6.23M | 8.19M |
Cash remaining | n/a | 20.25M | 20.69M | 16.99M | 20.97M | 19.01M |
Runway (months of cash) | n/a | 4.2 | 4.6 | 2.4 | 4.9 | 3.4 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Jun 22 | Raul R Rodriguez | Common Stock | Buy | Acquire P | No | No | 0.6884 | 1,000,000 | 688.4K | 1,391,776 |
20 May 22 | Moos Walter H | Common Stock | Grant | Acquire A | No | No | 0 | 25,000 | 0 | 52,222 |
20 May 22 | Moos Walter H | Stock Option Common Stock | Grant | Acquire A | No | No | 2.01 | 30,000 | 60.3K | 30,000 |
20 May 22 | Lapointe Anthony Gregg | Common Stock | Grant | Acquire A | No | No | 0 | 25,000 | 0 | 50,000 |
20 May 22 | Lapointe Anthony Gregg | Stock Option Common Stock | Grant | Acquire A | No | No | 2.01 | 30,000 | 60.3K | 30,000 |
20 May 22 | Lyons Gary A | Common Stock | Grant | Acquire A | No | No | 0 | 25,000 | 0 | 50,000 |
20 May 22 | Lyons Gary A | Stock Option Common Stock | Grant | Acquire A | No | No | 2.01 | 30,000 | 60.3K | 30,000 |
20 May 22 | Hannah Alison L. | Common Stock | Grant | Acquire A | No | No | 0 | 25,000 | 0 | 31,250 |
20 May 22 | Hannah Alison L. | Stock Option Common Stock | Grant | Acquire A | No | No | 2.01 | 30,000 | 60.3K | 30,000 |
Institutional ownership, Q1 2022
13F holders | Current |
---|---|
Total holders | 168 |
Opened positions | 20 |
Closed positions | 17 |
Increased positions | 51 |
Reduced positions | 55 |
13F shares | Current |
---|---|
Total value | 410.06M |
Total shares | 136.64M |
Total puts | 140.5K |
Total calls | 312.9K |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
FMR | 24.18M | $72.3M |
BLK Blackrock | 16.57M | $49.56M |
Vanguard | 9.13M | $27.31M |
STT State Street | 7.52M | $22.5M |
IVZ Invesco | 5.16M | $15.44M |
Rock Springs Capital Management | 4.92M | $14.72M |
Lord, Abbett & Co. | 4.41M | $13.19M |
Nuveen Asset Management | 4.15M | $13.39M |
Great Point Partners | 4M | $11.96M |
Citadel Advisors | 3.97M | $11.86M |
Financial report summary
?Competition
AMGEN • Curis • Novartis • Apellis Pharmaceuticals • Argen X SE • Kronos Bio • ImmunovantContent analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. senior Avg
|
New words:
Annora, calendar, Caribbean, Circuit, combat, delisted, delisting, distraction, dyspnea, exclusionary, foreclose, Forma, grace, Hetero, inflation, isocitrate, Jersey, Knight, Latin, letter, lien, Mexico, mutated, Nasdaq, olutasidenib, path, pathophysiology, PDUFA, penalizing, pyrexia, regain, revealing, SA, SOFR, sublicensing, synergistic, thethird, unascertainable, unasserted, USA, vi, vigorously, visit, wake
Removed:
begun, enrolling, HS, Incrementally, maintained, marketplace, palmoplantar, PPP, presidential, remained, sNDA, suppurativa, switch, topline
Financial reports
Current reports
8-K
Rigel Reports Second Quarter 2022 Financial Results and Provides Business Update
2 Aug 22
8-K
Other Events
25 Jul 22
8-K
Other Events
23 Jun 22
8-K
Rigel Announces Top-line Results from FORWARD Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia
8 Jun 22
8-K
Departure of Directors or Certain Officers
23 May 22
8-K
Rigel Reports First Quarter 2022 Financial Results and Provides Business Update
3 May 22
8-K
Rigel Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
1 Mar 22
8-K
Entry into a Material Definitive Agreement
17 Feb 22
8-K
Departure of Directors or Certain Officers
28 Jan 22
8-K
Rigel Pharmaceuticals Provides Business Update
10 Jan 22
Registration and prospectus
S-8
Registration of securities for employees
3 Aug 22
S-8
Registration of securities for employees
1 Mar 22
POS AM
Prospectus update (post-effective amendment)
1 Mar 22
POSASR
Automatic shelf registration (post-effective amendment)
1 Mar 22
S-3ASR
Automatic shelf registration
3 Aug 21
S-8
Registration of securities for employees
21 Jun 21
S-8
Registration of securities for employees
4 Aug 20
424B5
Prospectus supplement for primary offering
4 Aug 20
S-8
Registration of securities for employees
6 Aug 19
S-8
Registration of securities for employees
8 Aug 18
Proxies
DEFA14A
Additional proxy soliciting materials
5 Apr 22
DEFA14A
Additional proxy soliciting materials
1 May 20
DEFA14A
Additional proxy soliciting materials
1 Apr 20
DEFA14A
Additional proxy soliciting materials
9 Apr 19
DEF 14A
Definitive proxy
3 Apr 18
DEFA14A
Additional proxy soliciting materials
3 Apr 18
Other
EFFECT
Notice of effectiveness
4 May 22
CT ORDER
Confidential treatment order
24 Apr 20
CT ORDER
Confidential treatment order
24 Apr 20
CT ORDER
Confidential treatment order
16 Jan 20
CT ORDER
Confidential treatment order
15 Jan 20
CT ORDER
Confidential treatment order
15 Jan 20
CT ORDER
Confidential treatment order
20 Mar 19
CORRESP
Correspondence with SEC
1 Apr 18
EFFECT
Notice of effectiveness
1 Apr 18
UPLOAD
Letter from SEC
18 Mar 18
Ownership
SC 13G/A
RIGEL PHARMACEUTICALS / STATE STREET ownership change
11 Jul 22
4
RIGEL PHARMACEUTICALS / RAUL R RODRIGUEZ ownership change
13 Jun 22
4
RIGEL PHARMACEUTICALS / WALTER H MOOS ownership change
23 May 22
4
RIGEL PHARMACEUTICALS / Jane Wasman ownership change
23 May 22
4
RIGEL PHARMACEUTICALS / ANTHONY GREGG LAPOINTE ownership change
23 May 22
4
RIGEL PHARMACEUTICALS / GARY A LYONS ownership change
23 May 22
4
RIGEL PHARMACEUTICALS / ALISON L. HANNAH ownership change
23 May 22
4
RIGEL PHARMACEUTICALS / Kamil Ali-Jackson ownership change
23 May 22
4
RIGEL PHARMACEUTICALS / Brian L. Kotzin ownership change
23 May 22
SC 13G/A
RIGEL PHARMACEUTICALS / STATE STREET ownership change
13 Feb 22
Patents
Utility
Compounds and Method for Treating Cytokine Release Syndrome
11 Aug 22
Inventors: Vanessa Taylor, Sarkiz Issakani, Chi Young
Utility
RIP1 inhibitory compounds and methods for making and using the same
9 Aug 22
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Utility
Compounds and Method for Treating Autoimmune Diseases
14 Jul 22
Inventors: Esteban Masuda, Rajinder Singh, Vanessa Taylor, Donald G. Payan
Utility
RIP1 inhibitory compounds and methods for making and using the same
5 Jul 22
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Utility
Benzazole Compounds and Methods for Making and Using the Compounds
16 Jun 22
Disclosed are novel benzazole compounds and compositions comprising the compounds.
Transcripts
2022 Q2
Earnings call transcript
3 Aug 22
2022 Q1
Earnings call transcript
4 May 22
2021 Q4
Earnings call transcript
2 Mar 22
2021 Q3
Earnings call transcript
3 Nov 21
2021 Q2
Earnings call transcript
4 Aug 21
2021 Q1
Earnings call transcript
6 May 21
2020 Q4
Earnings call transcript
3 Mar 21
2020 Q3
Earnings call transcript
5 Nov 20
2020 Q2
Earnings call transcript
4 Aug 20
2020 Q1
Earnings call transcript
6 May 20
Reddit threads
If you had to pick 1 stock for the next 15 years what would it be? (Not ETF)
8 Aug 22
Daily Discussion Thread - August 2nd, 2022
2 Aug 22
Daily Discussion Thread - August 1st, 2022
1 Aug 22
Daily Plays July 01, 2022
1 Jul 22
Anyone on RIGL?
24 Jun 22
Daily Plays June 23, 2022
23 Jun 22
Daily Plays June 22, 2022
22 Jun 22
Daily Plays June 21, 2022
21 Jun 22
[Weekly Megathread] Markets and Value Stock Ideas, Week of June 20, 2022
20 Jun 22
Daily Plays June 17, 2022
17 Jun 22